Envy Medical Appoints Chief Marketing Officer to Executive Team

Shauna Lahiri, Will Drive Marketing Strategy For Continued Growth And Expansion

WESTLAKE VILLAGE, Calif., Feb. 23, 2015 /PRNewswire/ — Envy Medical Products, Inc., an emerging leader in specialized skincare products, announced today that Shauna Lahiri will be joining the company in the newly created role of Chief Marketing Officer.  Lahiri brings a 17-year record of building successful global marketing strategies, building and launching new brands achieving leadership in mass, consumer and niche categories. She will be responsible for marketing, e-commerce and digital media development.

SLahiri

Shauna Lahiri, Chief Marketing Officer. Envy Medical, Inc.

“Shauna is joining Envy at an exciting stage in our growth and company development,” said Curtis A. Cluff, Envy’s CEO.  “She has a uniquely powerful combination of strategic thinking and deep industry experience, particularly for bringing new products and technologies to market. We have what we believe is the most exciting portfolio in professional skincare today and Shauna brings exactly the skillset and high-level passion required for driving the success these technologies inherently deserve.”

“Envy Medical products have a strong value proposition for patients and consumers worldwide who are seeking highly effective skincare with multi-faceted functionality without downtime or safety concerns,” commented Lahiri.  “The entire skincare industry trend has been moving toward the positioning that Envy’s SilkPeel, Lumixyl and ClarityMD branded products already occupy; I am looking forward to expanding the company’s presence and stature in personal care markets world-wide.”

Lahiri began her career at Valeant Pharmaceuticals, developing the Kinerase® marketing platform while also leading management and marketing of pharmaceutical brands in psoriasis care and hormone replacement therapies. She then went on to become the Executive Director of International Marketing for Guthy-Renker LLC, driving the international division to become a $450 million entity in under six years. She led the international marketing team for all flagship brands such as Proactiv®, WEN® Hair Care, Meaningful Beauty®, and Sheer Cover®. Lahiri was then named a partner of In Response LLC, a direct-response beauty care company where she managed all brand development and launch strategies for their flagship hair care brand and developed all customer acquisition and retention campaign strategies. Since 2012, she has been the founder and Chief Global Brand Strategist of Ignition Beauty, providing executive level strategic guidance, marketing, brand and launch strategy for Health, Beauty, CPG, Pharmaceutical, Aesthetic, Direct-to-Consumer, E-commerce and Direct-Selling organizations. Her clients have included start-ups to some of the best-known beauty and personal care brands in the world.  Lahiri received her MBA from Wayne State University and has a BS in Commerce, Marketing and Business Policy from the University of Windsor.

Lahiri’s appointment follows the successful professional brand skincare launches of the Lumixyl Topical Brightening System of products, an innovative hydroquinone-free skin brightening range based on the proprietary Lumixyl Decapeptide-12 technology; ClarityMD Acne Solution, a natural botanical based 2-step acne system that clears acne exceptionally fast without causing the redness and irritation commonly found in other commercially available acne products.  In 2014, Envy raised new investment capital with HCP Capital Partners to further support the commercialization of the Envy technology portfolio.

About Envy Medical, Inc.
Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions.  The Company’s lead products include SilkPeel®, a breakthrough device combining exfoliation with Dermalinfusion® for deeper tissue delivery of active ingredients and better patient outcomes (www.silkpeel.com). Envy is also the developer of the patent pending ClarityMD Acne Solution brand of acne treatment products (www.claritymdacne.com) and is the exclusive worldwide licensor of skin brightening peptides including Lumixyl® (www.lumixyl.com). More information can be found at www.envymedical.com.

Photo – http://photos.prnewswire.com/prnh/20150223/177055

 

SOURCE Envy Medical, Inc.

 

Posted in News | Tagged , , , , , , , , , , | Leave a comment

Industry Experts Discuss Medical Aesthetic Trends

TAG10144

This Article appears in the Sept/October issue of The Aesthetic Guide.  To read the full article, go to the Digital Magazine Edition found HERE

TAG Cover Sept-Oct2014

The Aesthetic Guide September October 2014

Medical Aesthetics Trending Into an Extended Growth Phase

By Jeffrey Frentzen, Executive Editor The medical aesthetics industry has entered a new era of maturity, with overall solid growth in many segments, worldwide. Recent market research also suggests that in terms of growth we are seeing only a tip of the iceberg. Major manufacturers have rebounded strongly post-recession and consumer demand for all ranges of cosmetic or aesthetic procedures has shown healthy signs of growth, as well. The market is witnessing strong growth in energy-based device, body shaping and skin tightening segments. According to the market study, Global Aesthetic Market XII (Medical Insight, Inc., Aliso Viejo, Calif., April 2014), total worldwide sales of aesthetic products in 2013 exceeded $5.9 billion. Through 2018, they will expand by 11.5% per year to almost $10.2 billion. In North America, sales growth will remain strong at overall annual growth of 9.4% per year with total sales reaching $1 billion in 2018.

In addition, the industry is going through a period of significant change, according to Robert E. Grant, managing partner at Strathspey Crown Holdings LLC (Newport Beach, Calif.). “In medical aesthetics the only change is constant,” he said. “There’s a struggle for industry leadership, which we are watching between Allergan and Valeant. We are going to see more new technologies and important products appear. For instance, we’re certainly seeing that with the growth of Voluma, which has been significant for volumizing, as well as solid growth in neurotoxins and the popularity of CoolSculpting, which has gained some traction.”

Motivating this growth is a consumer trend that demands maximum affect with minimum down time and risks of side effects, expressed Curtis Cluff, CEO of Envy Medical, Inc. (Westlake Village, Calif.) “This is an area that was underserved, and the demand wasn’t as developed a few years ago because people didn’t know they could demand that. A number of products and technologies have set that expectation and this has led to an increased demand. It is creating a nice surge in the aesthetic medical space.”

Consumers now know what is available at what costs, the downtime and associated risks. They no longer wait until their later years to begin aesthetic treatments, as they understand early, non-surgical intervention is a means to preserving their youth and a means to postponing or avoiding surgery.

According to Nicholas L. Teti, Jr., president and CEO of Suneva Medical (Santa Barbara, Calif.), “The number of people who are now in the pool who perhaps were not in the pool five years, tens years, and definitely fifteen years ago were not there. So, I think the industry has quite healthy, and will be for a long time.”

This Article appears in the Sept/October issue of The Aesthetic Guide.  TO read the full order, go to the Digital Magazine Edition found HERE

Posted in News | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Envy Medical and Libbs Farmaceutica Partner For Lumixyl in Brazil

Envy Medical and Libbs Farmaceutica Announce Strategic Marketing, Sales and Distribution Agreement For Brazil

 

WESTLAKE VILLAGE, Calif. and SAO PAULO, July 22, 2014 /PRNewswire/ — Envy Medical and Libbs Farmaceutica today announced a strategic agreement to manufacture, market and sell Envy’s proprietary Lumixyl® Brightening Creme throughout the country of Brazil.

This is a significant milestone for Envy Medical’s professional skincare products, as it not only represents a significant agreement with Libbs, a leader in the sales and supply of pharmaceutical products, but it also represents a solid entry into the largest single skincare market outside of the United States.

LumixylGem

“The population of Brazil possesses a strong and growing demand for an effective alternative to hydroquinone, and particularly one without the side effects associated with prescription hydroquinone,” said Curtis A. Cluff, CEO of Envy Medical, Inc. “I am particularly excited to work with Libbs, as they are a major force and a partner of unparalleled capability, ethics, and integrity.”

Products that can effectively address hyperpigmentation and photo-damage are in demand in the country, which not only has a large Latin population more genetically disposed to hyperpigmentation issues, but also the largest population of Japanese descent outside of Japan. For women (and increasingly men) of either heritage, a clear, more even skin tone is culturally important in building a stronger sense of confidence and self-esteem.

“We are pleased to bring this safe and effective skincare technology for brighter and more even skin-tone to the women and men of Brazil,” said Alcebiades de Mendonca Athayde Junior, CEO of Libbs. “The Lumixyl Brightening Creme has tested extremely well with our initial focus groups and dermatologists, both in terms of its efficacy and unique aesthetic qualities.”

The agreement was also facilitated by Aime Medical, Inc., a Clearwater, Florida-based company that acted as Envy’s international agent in identifying Libbs as the premier partner for Lumixyl in Brazil, and thereafter assisting with product launch and training activities.

Under the agreement, Libbs and Envy have collaborated in developing manufacturing capabilities for Envy products in Brazil, with Libbs leading the way in executing a tailored branding and sales strategy. The Lumixyl Brightening Creme will arrive at the Brazilian market at a suggested retail price of R$140 for a 30ml bottle. Libbs has already made the product available in over 3,000 retail drugstores and specialty pharmacies throughout Brazil with future distribution expansion plans.

ABOUT LIBBS FARMACEUTICA — Since 1958, Libbs Farmaceutica has grown into one of the top Brazilian pharmaceutical companies, with expertise in drug deployment, marketing and product management, using its a 585-member sales-force. The company’s business strategy is to pursue business where its assets can complement drug development or placement of a drug in the market.  The company has established core competencies in the areas of cardiovascular, gynecology, central nervous system, dermatology, oncology, respiratory & gastroenterology. More information on Libb’s launch of Lumixyl can be found at www.lumixyl.com.br .

ABOUT ENVY MEDICAL — Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions.  The Company’s lead products include SilkPeel®, a breakthrough device combining exfoliation with Dermalinfusion® for deeper tissue delivery of active ingredients and better patient outcomes ( www.silkpeel.com ). Envy is also the developer of the patent pending ClarityMD Acne Solution brand of acne treatment products (www.claritymdacne.com ) and is the exclusive worldwide licensor of skin brightening peptides including Lumixyl®, developed at Stanford University ( www.lumixyl.com ). More information can be found at www.envymedical.com .

Photo – http://photos.prnewswire.com/prnh/20140721/128964

SOURCE Envy Medical

Copyright (C) 2014 PR Newswire. All rights reserved

 

Posted in Lumixyl, News | Tagged , , , , , , , , , , , , | 1 Comment

ClarityMD Acne Solution Shown Effective In New Study

New Journal of Drugs In Dermatology Published Study Shows ClarityMD To Be Highly Effective In Treating Inflammatory And Non-Inflammatory Acne

ClarityMDWESTLAKE VILLAGE, Calif.June 11, 2014 /PRNewswire/ — Envy Medical, Inc., a leader in professional skincare products and services, is excited to announce the publication of a new study in the June issue of the Journal of Drugs in Dermatology (JDD) proving the superior efficacy of its highly innovative acne system – ClarityMD. Designed by Envy Medical, Inc., the clinical study proves that ClarityMD is effective in quickly and gently clearing both inflammatory and non-inflammatory acne within days.

Already known for its blemish blasting speed, ClarityMD works up to three times faster than leading acne products. The easy two-step system combines the potent combination of salicylic acid, bakuchiol, and bisabolol in a Deep Pore Cleanser and Clarifying Gel to treat acne in two simple steps.  It also contains anti-aging ingredients and exfoliants such as Glycolic acid to help skin to look and feel better immediately and increase radiance over time.

Conducted by an independent group of researchers, the study results indicate clearance of acne lesions at an unprecedented pace. On average, 59% of acne in subjects was cleared in the first seven days, with 91.6% acne eradication achieved in 14 days. Participants’ skin had virtually complete acne clearance of 98.5% over the six-week study.

[box] “This all adds up to a highly effective new tool for treating acne, that also meets the demands of adult acne sufferers who want a skincare regimen that will clear and prevent acne while actually improving the tone and texture of skin.”[/box]

In addition to its remarkably fast-acting formulation, ClarityMD marks a significant innovation for acne sufferers because it eliminates the irritation generally associated with treating the affliction. Most acne studies involving prescription or over-the-counter (OTC) acne products show that these tend to over-dry skin and increase redness and irritation over the course of treatment.

“The biggest hurdle in the treatment of acne is patient non-compliance due to intolerance and irritation cause by many acne medications,” said Felipe Jimenez, Ph.D., Envy Medical’s Chief Scientific Officer. “This study is significant because it proves that acne medications don’t need to be harsh to be effective. Results demonstrated that ClarityMD clears acne with unprecedented speed and that any redness or irritation the study volunteers were experiencing from their acne prior to starting the study dissipated within the first 14 days.”

ClarityMD is also one of the few products to also show a significant positive effect on non-inflammatory acne (blackheads/whiteheads), showing over 56% reduction over the six-week period.

According to Ashish C. Bhatia, M.D., FAAD, the lead author of the study and Medical Director for Dermatologic Research at the DuPage Medical Group in Naperville, IL., “This all adds up to a highly effective new tool for treating acne, that also meets the demands of adult acne sufferers who want a skincare regimen that will clear and prevent acne while actually improving the tone and texture of skin.”

ABOUT ENVY MEDICAL

Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company’s lead products include SilkPeel®, a breakthrough device combining exfoliation with Dermalinfusion® for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive global licensor of skin brightening peptides including Lumixyl®, developed at Stanford University. The Lumixyl peptide is now also available as a topical solution for SilkPeel procedures, addressing hyperpigmentation and photo-damage. More information can be found at www.envymedical.com.

testimonial

CMD Expert Mickey Williams

Posted in ClarityMD | Tagged , , , , , , , , , | Leave a comment

Envy Medical Announces Growth Capital Investment

Envy-Top-Image-FINAL-1_00000WESTLAKE VILLAGE, Calif.June 4, 2014 /PRNewswire/ — Envy Medical, Inc., a leader in professional skincare products and services, announced today that it has secured new growth capital from HCP & Company, a middle-market private equity firm headquartered in Chicago. The new funding will support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of exciting new skincare offerings designed to meet the growing demand for healthier skin tone, texture, and function.

“This is the first time in Envy’s history that we have taken on outside growth capital, and we did so with unanimous board and shareholder support,” said Curtis A. Cluff, Chief Executive Officer. “That support is due in large part to HCP’s business acumen and an understanding that they bring significant experience to the table as Envy accelerates growth towards becoming a major global player in the specialized skincare market.”

HCP has developed its expertise in the personal care and beauty segments, working with high growth/large market potential companies that require capital to accelerate growth. Their investment is targeted primarily for that purpose.

“Looking across the professional skincare and physician dispensed markets, we recognize how very well positioned Envy is to be a dominant player in its market,” commented Carlos Signoret, HCP Partner and Co-founder. Jim Bland, HCP Principal added, “HCP is proud to be partnering with a talented and innovative Envy management team.”

“This is an exciting time for the Company,” said Ken Karasiuk, Envy Founder and Chairman of the Board. “SilkPeel is a superior non-invasive microdermabrasion technology that is safe and effective for all skin-types. Lumixyl is one of the first real alternatives to the increasingly controversial hydroquinone products more typically dispensed for the treatment of skin tone irregularities. Additionally, the ClarityMD Acne Solution has proven not only to be effective, but also to enjoy overwhelmingly positive patient feedback and acceptance.”

Acting as advisors for the transaction were Intrepid Investment Bankers, LLC. With this capital investment, Envy will continue its commitment to developing cutting edge aesthetic and therapeutic skincare offerings for dermatologists, as well as other medical skincare professionals and their patients.

ABOUT ENVY MEDICAL — Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company’s lead products include SilkPeel®, a breakthrough device combining exfoliation with Dermalinfusion® for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive global licensor of skin brightening peptides including Lumixyl®, developed atStanford University. The Lumixyl peptide is now also available as a topical solution for SilkPeel procedures, addressing hyperpigmentation and photo-damage. More information can be found at www.envymedical.com.

ABOUT HCP & Company — HCP & Company is a private equity firm specializing in growth equity and buyout investments in companies with attractive growth prospects. HCP seeks to generate sustainable, long-term value for its partners through sector-specific (consumer products, education and healthcare services) investment strategies. The firm has approximately $215 millionin assets under management. More information can be found at www.hcpcompany.com.

SOURCE Envy Medical, Inc.

SILKPEELAGING

Posted in News | Tagged , , , , , , , , , , , , , , , | Leave a comment

Medical and Beauty Experts Alike, Praise The New Acne Breakthrough

ClarityMD Acne Solution is being praised by Dermatologists who have seen the results on their patients, as well as Beauty Experts and Celebrity Makeup Artists who have longed for the right adult skincare products to give their clients to clear up skincare concerns while also promoting beautiful skin tone and texture.   ClarityMD is that product and it has a lot of people talking!  Here are just a few examples:

 Click Here to See Mickey Williams on Fox 4 Morning News

CMD Expert Mickey Williams

Click Here to See Kishana On The Morning Blend
CMD Expert Kishana Holland Johnson

Click Here to See Sheila on Your Carolina TV Program
CMD Expert Sheila Arway

See Nicole On WGN Beauty News TelevisionCMD Expert Nicole Pearl

See Sarah on The Windy City Live Television ProgramCMD Expert Sarah Eggenberger

Click Here to Find Out More About Dr. Julie Woodward, MD
CMD Expert Julie Woodward MD

Envy Medical, Inc. is the company that has launched the ClarityMD™ Acne Solution, a 2-step acne treatment system. The unique combination of bakuchiol, bisabolol and salicylic acid in the ClarityMD System clears acne three times faster than leading products without drying and irritating the skin.

For more on ClarityMD Acne Solution visit www.claritymdacne.com

About Envy Medical, Inc.
Envy has already laid the foundation for powerful global growth with SilkPeel and Lumixyl Products now available in over 35 countries around the world and the launch of the new ClarityMD for mild to moderate acne. Lumixyl is on track to be the only “professional” skincare brand actively marketed in all 5 of the major global skincare markets (North America, Europe, Japan, China and Brazil) by early 2014. Envy is currently the owner or exclusive licensor of 13 patents covering a rich pipeline of specialized skin care treatments applicable to medical and consumer markets around the world.

Posted in ClarityMD | Tagged , , , , , , , , , , , , , , | Leave a comment

Kym Douglas Shares Skin Brightening Secrets

Kym Douglas Shares Skin Brightening Secrets on Hallmark‘s Popular Home & Family Daytime Program

Hollywood’s Beauty and Lifestyle Expert Kym Douglas joined Home & Family Hosts Cristina Ferrare and Mark Steins on the set of the popular daytime program to share her latest discovery for brighter healthier skin.

Beauty  Lifestyle Expert Kym Douglas

Beauty Lifestyle Expert Kym Douglas

Kym noted that Brightening is the trending topic in beauty for spring 2014. People are no longer looking for an artificially tanned look (that often turn your skin orange – something hilariously illustrated in this segment!). No, this spring people want to get rid of the sun damage, the discoloration and they want to brighten their natural facial complexion to a healthy glow with one even healthy tone.

In sharing her latest discovery, Kym noted “This is a wonderful new brand I found called Lumixyl. It is a four-part system, and I love this kind of thing because it gives you everything in one.”

She walked Cristina and Mark through the four simple steps to a brighter complexion including 1) ActivePrep – an anti-oxidant rich non-soap cleanser that is designed ensure there are none of the skin irritants that can contribute to hyperpigmentation; 2) Brightening Creme – cream with a Stanford developed peptide that fades the appearance dark spots and freckles safely and effectively; 3) GlycoPeel – a rapid exfoliating lotion that you put on after the brightening cream and leave on to stimulate faster cellular turnover in skin, getting to the healthier new skin underneath; and finally, 4) Moisturelock SPF 30 – a rich feeling, moisturizing sunscreen which has no chemical sunscreen agents so it wont irritate skin prone to hyperpigmentation as well.

Kym also shared other tips – such as ensuring that you remove all of your makeup at the end of each day so it does not irritate your skin and clog your pores – contributing to skin damage and premature aging.

The other trick Kym shared was to take her cleanser and add an equal part baking soda for a natural exfoliator to use to get some extra exfoliation out of your morning or evening routine.

Lumixyl is available through dermatologists and plastic surgeons as well as medi-spa locations nationwide.   For more information on where you can purchase Lumixyl go to www.lumixyl.com and select the physician locator – where you can in put your city/town and state for a listing nearby.

New Image

Posted in Lumixyl, News | Tagged , , , , , , , , , , , , , , , | Leave a comment

American Laser Skincare Launches SilkPeel® Technology in Select Boston Locations

American Laser Skincare Launches Cutting-Edge Palomar Icon® and SilkPeel® Technology in Select Boston Locations

New Offerings Enhance American Laser Skincare’s Suite of Services to Ensure Clients Have Smooth Skin All Year Round

BOSTON, March 6, 2014 /PRNewswire/ — American Laser Skincare today announced that is has selected four Boston area clinics for a field test of two additions to its skin rejuvenation service portfolio. Peabody, Worcester, Braintree and Boston (Newbury Street) will be the first clinics in the country to test the Palomar Icon®  and Envy SilkPeel® skincare systems.

“Boston is a dynamic market. We believe our aesthetic skincare customers here are quite discerning,” said Dr. Paul Flashner, chief medical director for American Laser Skincare and medical director for the Boston area. “We’re excited to share these new products and give our local clientele the chance to experience them.”

The Palomar Icon Aesthetic System uses state-of-the-art laser and optimized light technology to treat hyperpigmentation, rosacea, facial vascular lesions, surgical scars, fine lines, wrinkles and stretch marks. It includes the Skintel® Melanin Reader, the only FDA-approved melanin reader, which determines the average melanin density of skin. The Icon also contains a built-in cooling system, allowing more energy to be delivered with less pain. The result is more customizable treatments, yielding a safer, more comfortable and more effective user experience in up to 50 percent less time required by other systems.

SilkPeel is a unique microdermabrasion technology that is the only medical-grade in-office procedure to use patented dermalinfusion technology. This allows SilkPeel to treat a wider variety of skin conditions. The process uses a diamond-tipped hand piece to remove the top layer of skin while simultaneously infusing the skin with a potent topical SilkPeel serum. Microdermabrasion is one of the top five non-surgical procedures performed nationally. Envy Medical’s unique SilkPeel protocol allows it to expand on traditional microderm benefits to treat acne, hyperpigmentation, dry skin, stretch marks, as well as combat signs of aging in the face and body.

“Palomar Icon and SilkPeel are two of the most cutting-edge technologies available in skincare today and something we want to share with our clients,” Flashner said. “This is just another example of how American Laser Skincare constantly looks to provide the best technology, services and skincare expertise, helping our customers look and feel their best.”

 

Read more:  http://www.digitaljournal.com/pr/1776418#ixzz2vG8ld9Ib

SOURCE American Laser Skincare

silkpeel image C

Posted in silkpeel, SilkPeel Dermalinfusion | Tagged , , , , , , , , , , , , | Leave a comment

Lumixyl and SilkPeel Benefits Shown in Skin Of Color

dark-skin-light-skin-pic_edited-3The benefits of SilkPeel have been well documented in recent years for treating a variety of skin conditions, from acne and acne scarring, to hyperpigmentation and other skin tone/texture issues.  This month, the Journal of Drugs in Dermatology provided further evidence of these benefits for patients with darker skin-types in a feature case report, authored by a very accomplished team of leading dermatologists including Ashish Bhatia MD (of Northwestern University, Chicago, IL), Jeffrey TS Hsu MD (of Dartmouth Medical School, Hanover, NH) and Basil M. Hantash MD, PhD (Stanford University trained founder of the Elixir Institute of Regenerative Medicine, San Jose, CA).

The feature publication is titled “Combined Topical Delivery and Dermalinfusion of Decapeptide-12 Accelerates Resolution of Post-Inflammatory Hyperpigmentation in Skin of Color”.  Dermalinfusion is the clinical name for the SilkPeel MD, a popular face and body rejuvenation procedure performed by dermatology and cosmetic surgery professionals all over the world.  Decapeptide-12 is the generic name for the Lumixyl peptide, a Stanford University discovered peptide that has been shown to minimize the appearance of dark spots, age spots and other skin discoloration conditions (collectively called “hyperpigmentation”).  In this case study, the patient was treated with the SilkPeel, which abrades the skin, peeling way the surface layer, while forcing a Lumixyl peptide solution into the deeper layers of skin where it can be most effective.

Base Line - 12 Weeks - 16 Weeks  Pictures courtesy of Dr. Ashish Bhatia (Naperville, IL.)

Base Line – 12 Weeks – 16 Weeks Pictures courtesy of Dr. Ashish Bhatia (Naperville, IL.)

According the the study authors, “The combined use of topical delivery and dermalinfusion® of decapeptide-12 represents a novel, safe, and efficacious noninvasive approach to achieve accelerated resolution of post-inflammatory hyperpigmentation (PIH), an especially difficult to treat and common dermatoses in skin of color.”

The patient pictured in the study, as is common with many people and particularly women with skin of color, suffered from hyperpigmented skin that occured as a result of simple acne break-outs, and lingered on the skin long after the acne itself had healed.  This is one of the more common forms of PIH, due in part to the commonality of acne itself, even in women that are well into their 30’s or 40’s.  The patchy discoloration is more commonly found in darker skin types that are genetically prone to experiencing hyperpigmentation whenever the skin is traumatized, whether by acne, sun-damage, medical laser procedures, or some other unintended skin injury.

In this case the patient received four SilkPeel procedures using the Lumixyl serum (a solution commonly used by physicians who provide SilkPeel procedures), spaced 2 weeks apart.  The SilkPeel treatment generally takes about 20 minutes to perform, and is non-invasive (so there is no “down time” for the patient).  The patient additionally applied the Lumixyl Brightening Creme twice daily in between SilkPeel treatments, and achieved complete visual clearance of the PIH over the course of six weeks.

The SilkPeel technology was developed by Envy Medical, Inc. in 2004, and has since grown to be one of the most popular non-invasive medical skincare procedures in the country, while also spreading to over 35 countries worldwide.  It is used and endorsed by a litany of leading dermatologists as well as plastic surgeons, due to its versatility in treating a wide variety of skin conditions and, as this most recent publication indicates, also due to its ability to treat a wide variety of skin types safely and effectively.

SilkPeel is the only in-office procedure that incorporates the Lumixyl peptide technology for the treatment of skin tone issues.  Lumixyl is incorporated into a line of skincare products that promote healthy skin function and an even skin tone.  Lumixyl fits well with the SilkPeel technology because it too is supported by an expansive body of studies, and it too has become popular in the treatment of skin tone and texture issues.  It is known by physicians and their patients as the safe and effective alternative to prescription hydroquinone (HQ) products commonly prescribed.  Unlike hydroquinone, results can be achieved with Lumixyl without the risk of side effects, and without safety concerns associated with longer term HQ use.

For more information on SilkPeel go to SilkPeel.com, while more information on the Lumixyl peptide technology and skincare can be found at Lumixyl.com.  This case report is available at the JDD’s online publication.

Posted in Lumixyl, silkpeel | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Breaking News: Hydroquinone Products Halted in Five States

banned

Several HQ Skincare products will no longer ship to TX, NY, MA, MT or NH.

Reports have been streaming in from physicians and their staff throughout New York, Massachusetts, New Hampshire, Montana, and Texas.  What they are reporting is that they have been notified by Obagi Medical Products (now a division of Valeant Pharmaceuticals), that starting November 1, 2013, they will no longer be shipping any of their hydroquinone products to physicians in those states.

This effectively means an immediate moratorium on the Obagi Nuderm system, Obagi CRx system, and the Elastiderm Décolletage system, and any parts of those systems that actually contain hydroquinone.  The notice does not appear to give an explanation as to why action has been taken in those states specifically and not others.  Texas is the least surprising due to the fact that the Texas district attorney has tangled with Obagi in the past, blocking their ability to ship into the state at times.  More recently, Texas Governor Rick Perry vetoed a bill that would legally clear the way for companies like Obagi to sell products to physicians for dispensing, citing public safety concerns (details of that story found here).

However, no such public issue has been foreshadowed for the other states.  Some have surmised that with the success of new alternatives to hydroquinone for treating hyperpigmentation, and perhaps also due in part to recent lawsuits against doctors and/or manufacturers of hydroquinone products brought by individuals claiming to have suffered permanent side effects, larger companies may be limiting their sales and distribution through physicians as a precaution.

For those physicians that still use and recommend hydroquinone products in their practices, the primary advice is to ensure each patient is informed of the potential for side effects (even if such potential is considered unlikely), and that they are informed of the available alternatives for addressing skin tone issues such as melasma, photo-damage, age spots and PIH.  Doing so and documenting it will help limit liabilities should the patient become dissatisfied with the outcome of such product use.

The other advice for hydroquinone prescribing doctors?  Ensure your patients take a break from using it every couple of months, for a few months.  This will help reduce the risk of resistance issues, and what some doctors describe as severe rebounding (a return of melasma in the skin after use, that become more stubborn, and therefore harder to treat than the original occurrence).  Here again, having a non-hydroquinone skin brightener will help immensely by giving the patient a maintenance regimen to keep and improve upon the progress they have made in clearing up their skin discolorations.

The ongoing trend in removing hydroquinone from commercial skincare products appears to remain firmly in place in the United States, as it has been (dating back further) in many countries around the world.  This latest news comes as a surprise some, as well as being a headache and disruption to their practice.  However disturbing, it appears to be just one more step in the same road we have been traveling.

Stay tuned, there will be more to report as this story develops.

Posted in News, obagi | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment